Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients

Clinical Cancer Research

Volumn 17, Issue 19, 2011, Pages 6329-6337

  Azzopardi, Nicolas ^a,b   Lecomte, Thierry ^a,b,c   Ternant, David ^a,b,c   Boisdron Celle, Michelle ^d   Piller, Friedrich ^e   Morel, Alain ^d   Gouilleux Gruart, Valérie ^a,b,c   Vignault Desvignes, Céline ^a,b,c   Watier, Hervé ^a,b,c   Gamelin, Erick ^d   Paintaud, Gilles ^a,b,c  

^a UNIVERSITÉ DE TOURS   (France)

^b CNRS   (France)

^c Department of Hepato Gastroenterology ^*  (France)

^d Team 12   (France)

^e CENTRE DE BIOPHYSIQUE MOLÉCULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; SERUM ALBUMIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; COMPARTMENT MODEL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HAND FOOT SYNDROME; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK FACTOR; SKIN DISEASE; SKIN TOXICITY; TUMOR LOCALIZATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 80053524138     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1081     Document Type: Article

References (37)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30. (Pubitemid 40310185)
2. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8. (Pubitemid 41079832)
3. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45. (Pubitemid 38944402)
4. Lenz HJ, van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006;24:4914-21. (Pubitemid 46630920)
5. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-5.
6. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to antiepidermal growth factor receptor antibody therapies. Cancer Res 2007;67:2643-8. (Pubitemid 46548951)
7. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007;96:1166-9. (Pubitemid 46625066)
8. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008;19:508-15. (Pubitemid 351325672)
9. Qiu LX, Mao C, Zhang J, Zhu XD, Liao RY, Xue K, et al. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies. Eur J Cancer 2010;46:2781-7.
10. Fracasso PM, Burris H III, Arquette MA, Govindan R, Gao F, Wright LP, et al. A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res 2007;13:986-93. (Pubitemid 46340377)
11. Ma P, Yang BB, Wang YM, Peterson M, Narayanan A, Sutjandra L, et al. Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors. J Clin Pharmacol 2009;49:1142-56.
12. Ternant D, Paintaud G. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther 2005;5 Suppl 1:S37-47. (Pubitemid 41243344)
13. Boisdron-Celle M, Remaud G, Traore S, Poirier AL, Gamelin L, Morel A, et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett 2007;249:271-82. (Pubitemid 46452935)
14. Gamelin E, Delva R, Jacob J, Merrouche Y, Raoul JL, Pezet D, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 2008;26:2099-105.
15. Gamelin E, Boisdron-Celle M, Delva R, Regimbeau C, Cailleux PE, Alleaume C, et al. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol 1998;16:1470-8. (Pubitemid 28175768)
16. Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 2004;10:5151-9. (Pubitemid 39099790)
17. Dall'Ozzo S, Andres C, Bardos P, Watier H, Thibault G. Rapid single-step FCGR3A genotyping based on SYBR Green I fluorescence in real-time multiplex allele-specific PCR. J Immunol Methods 2003;277:185-92. (Pubitemid 36694384)
18. Ceze N, Ternant D, Piller F, Degenne D, Azzopardi N, Dorval E, et al. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab. Ther Drug Monit 2009;31:597-601.
19. Lavielle M, Mentre F. Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software. J Pharmacokinet Pharmacodyn 2007;34:229-49. (Pubitemid 46536259)
20. Panhard X, Samson A. Extension of the SAEM algorithm for nonlinear mixed models with 2 levels of random effects. Biostatistics 2009;10:121-35. (Pubitemid 352847911)
21. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18:904-14. (Pubitemid 30106623)
22. Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:3234-43. (Pubitemid 32591441)
23. Tan AR, Moore DF, Hidalgo M, Doroshow JH, Poplin EA, Goodin S, et al. Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. Clin Cancer Res 2006;12:6517-22. (Pubitemid 44799726)
24. Dirks NL, Nolting A, Kovar A, Meibohm B. Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck. J Clin Pharmacol 2008;48:267-78. (Pubitemid 351257778)
25. Tabernero J, Ciardiello F, Rivera F, Rodriguez-Braun E, Ramos FJ, Martinelli E, et al. Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. Ann Oncol 2010;21:1537-45.
26. Bonate PL. The effect of collinearity on parameter estimates in nonlinear mixed effect models. Pharm Res 1999;16:709-17. (Pubitemid 29227102)
27. Maitre PO, Buhrer M, Thomson D, Stanski DR. A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam. J Pharmacokinet Biopharm 1991;19:377-84.
28. Webster-Gandy JD, How C, Harrold K. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs 2007;11:238-46.
29. Bergstrand M, Karlsson MO. Handling data below the limit of quantification in mixed effect models. Aaps J 2009;11:371-80.
30. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008;84:548-58.
31. Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 2008;62:779-86.
32. Fasanmade AA, Adedokun OJ, Ford J, Hernandez D, Johanns J, Hu C, et al. Population pharmacokinetic analysis of infliximab in patientswith ulcerative colitis. Eur J Clin Pharmacol 2009;65:1211-28.
33. Chaudhury C, Mehnaz S, Robinson JM, Hayton WL, Pearl DK, Roopenian DC, et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med 2003;197:315-22. (Pubitemid 36184238)
34. Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009;27:1122-9.
35. Peeters M, Siena S, van Cutsem E, Sobrero A, Hendlisz A, Cascinu S, et al. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 2009;115:1544-54.
36. Amado RG, Wolf M, Peeters M, van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
37. van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.